Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population

Camille C.B. Kockerols,Peter JM Valk,Nicole M A Blijlevens,Jan J. Cornelissen,Avinash G. Dinmohamed,Inge Geelen,Mels Hoogendoorn,Jeroen J.W.M. Janssen,Laura G.M. Daenen,Bert A. van der Reijden,Peter E. Westerweel

Blood（2022）

引用 0|浏览4

暂无评分

摘要

We recommend BCR::ABL1 KD mutation testing in particular in the context of primary or secondary resistance. IC50-values can direct the TKI choice for CML patients, but clinical efficacy can be seen despite adverse in vitro resistance.

查看译文

关键词

kinase domain mutation testing,chronic myeloid leukemia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要